The Weight-Loss Pill Era: Novo's Wegovy Tablet Tops Three Million Scripts.
Novo Nordisk (NVO) said prescriptions for its Wegovy weight-loss pill have surpassed three million — a big number for an oral version of a treatment that until recently mostly meant injections.
Based on WSJ reporting · Capital Wealth analysis by Sean Anees Saifi · June 9, 2026
A modern pharmacy counter with neatly arranged unlabeled white pill bottles.
The Story
Novo Nordisk (NVO) said prescriptions for its Wegovy weight-loss pill have surpassed three million — a big number for an oral version of a treatment that until recently mostly meant injections. A pill is far easier to start and stick with, which is how a good drug becomes a blockbuster. The flip side showed elsewhere in the race: Zealand Pharma fell after nearly a fifth of patients in a late-stage obesity-shot study dropped out over gastrointestinal side effects.
What This Means For The Book
The GLP-1 wave remains one of the strongest secular growth stories in healthcare. We get our exposure through the two leaders — Novo Nordisk (NVO) and Eli Lilly (LLY) — both reinforced, and we watch the also-rans for stumbles.
